# US 2010/0168012 A1 · Human cancer therapy using engineered matrix metalloproteinase-activated anthrax lethal toxin that targets tumor vasculatuture

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168012 A1
- Document ID: US20100168012A1
- Status: Published application
- Kind: A1
- Application number: 12/519,362
- Filed: 2007-12-14
- Published: 2010-07-01
- Earliest claimed: 2006-12-14
- Assignees: The Government of the United States of America as represented by the Secretary of the Department of
- Inventors: Stephen H. Leppla; Shihui Liu; Thomas H. Bugge; Brooke M. Curie
- Web page: https://patentgrep.com/patent/US20100168012A1

## CPC

- A61K 38/164: {from bacteria}
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides methods for inhibiting tumor associated angiogenesis by administering a mutant protective antigen protein comprising a matrix metalloproteinase-recognized cleavage site in place of the native protective antigen furin-recognized site in combination with a lethal factor polypeptide comprising a protective antigen binding site. Upon cleavage of the mutant protective antigen by a matrix metalloproteinase, the lethal factor polypeptide is translocated into cancer and endothelial cells and inhibits tumor associated angiogenesis.

## Claims

### Claim 1

A method of inhibiting tumor associated angiogenesis in a subject, the method comprising the steps of:
(1) administering to the subject a therapeutically effective amount of a mutant PA protein comprising a matrix metalloproteinase 2-recognized cleavage site in place of the native PA furin-recognized cleavage site, wherein the mutant PA is cleaved by a matrix metalloproteinase; and
(ii) administering to the subject a therapeutically effective amount of an LF polypeptide comprising a PA binding site; wherein the LF polypeptide binds to cleaved PA and is translocated into a tumor associated endothelial cell, thereby inhibiting tumor angiogenesis.

### Claim 2 (depends on 1)

The method of claim 1, said tumor is a solid tumor.

### Claim 3 (depends on 2)

The method of claim 2, wherein said solid tumor is selected from the group consisting of lung cancer, colon cancer, melanoma, breast cancer, bladder cancer, thyroid cancer, liver cancer, pleural cancer, pancreatic cancer, ovarian cancer, cervical cancer, fibrosarcoma, neuroblastoma, and glioma.

### Claim 4 (depends on 2)

The method of claim 2, wherein said solid tumor is selected from the group consisting of lung cancer, colon cancer, and melanoma.

### Claim 5 (depends on 1)

The method of claim 1, wherein the LF polypeptide is native LF.

### Claim 6 (depends on 1)

The method of claim 1, wherein the LF polypeptide is LFn.

### Claim 7 (depends on 1)

The method of claim 1, wherein the LF polypeptide is a fusion protein.

### Claim 8 (depends on 1)

The method of claim 1, wherein the mutant PA protein and the LF polypeptide are administered systemically to the subject.

### Claim 9 (depends on 1)

The method of claim 1, wherein said matrix metalloproteinase 2 cleavage site has the sequence GPLGMLSQ.

### Claim 10 (depends on 1)

The method of claim 1, wherein said mutant PA is cleaved by a matrix metalloproteinase 2 from endothelial cells.

### Claim 11 (depends on 1)

The method of claim 1, wherein said PA and LF, after translocation into a tumor associated endothelial cell, induces apoptosis of said endothelial cell.

### Claim 12 (depends on 1)

The method of claim 1, wherein said endothelial cell has an activated MAP kinase pathway.

### Claim 13 (depends on 1)

The method of claim 1, wherein said translocated LF polypeptide and cleaved PA results in cleavage of a MEK selected from the group consisting of MEK1, MEK2, MEK3, MEK4, MEK6, and MEK7.

### Claim 14 (depends on 1)

The method of claim 1, wherein said mutant PA is further cleaved by a matrix metalloproteinase 2 from a tumor cell.

### Claim 15 (depends on 14)

The method of claim 14, wherein said LF polypeptide binds to cleaved PA and is translocated into the tumor cell.

### Claim 16 (depends on 15)

The method of claim 15, wherein said translocated LF polypeptide and cleaved PA inhibit the expression of IL-8 mRNA in the tumor cell.

### Claim 17 (depends on 14)

The method of claim 14, wherein said tumor cell has an activated MAP kinase pathway.

### Claim 18 (depends on 17)

The method of claim 17, wherein said activated MAP kinase pathway is due to a BRAF V600E mutation.

### Claim 19 (depends on 15)

The method of claim 15, wherein said translocated LF polypeptide and cleaved PA results in cleavage of a MEK selected from the group consisting of MEK1, MEK2, MEK3, MEK4, MEK6, and MEK7.
